HUDCO Q1 Results: Net profit jump 13% YoY to Rs 630.2 crore, NII up 11.2% YoY
Revenue from operations stood at ₹2,937.31 crore, compared to ₹2,188.35 crore in Q1 FY25, showing a year-on-year increase of 34.23%. Total income, including other income, rose to ₹2,945.47 crore from ₹2,197.19 crore, up 34.06%. Net interest income (NII) for the quarter came in at ₹961 crore, compared to ₹724.7 crore in the same quarter last year, up 11.2%.
Profit before tax stood at ₹857.23 crore, up from ₹684.70 crore, showing a growth of 25.22% year-on-year. Net profit for the quarter was ₹630.2 crore compared to ₹558 crore in Q1 FY25, an increase of 13%.
EBITDA for the quarter stood at ₹2,828.32 crore, rising 32% from ₹2,141.51 crore in Q1 FY25. EBITDA margin came in at 96.3%, slightly lower than 97.9% in the previous year.
On the asset quality front, the gross NPA ratio improved to 1.34% from 2.42% in Q1 FY25, while net NPA dropped to 0.09% from 0.33% a year earlier.
The company also declared its first interim dividend for the financial year 2025–26. A dividend of ₹1.15 per equity share (i.e., 11.50% on the face value of ₹10 per share) has been approved, subject to deduction of TDS. The record date for determining the eligibility of shareholders for receiving this dividend has been fixed as Thursday, 14th August 2025.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
7 hours ago
- Business Upturn
Como all set to sign Álvaro Morata as their new centre striker
Como have agreed a deal to sign Álvaro Morata from Galatasaray on a few close to €5 million. By Ravi Kumar Jha Published on August 8, 2025, 19:20 IST Como have agreed a deal to sign Álvaro Morata from Galatasaray on a few close to €5 million. The striker has agreed to join them as he wants a change. Galatasaray signed Victor Osimhen this summer which means they will not need two starters in one squad. Thus, they decided to let Morata leave. Serie A side Como have reached an agreement to sign Álvaro Morata from Galatasaray in a deal worth close to €5 million. The Spanish striker has agreed to make the switch as he seeks a fresh challenge in his career. Galatasaray, who brought in Victor Osimhen earlier this summer, decided to part ways with Morata to avoid having two starting strikers competing for one spot. The 31-year-old forward spent just one season in Turkey, helping the club in their domestic and European campaigns, but will now head to Italy as Como prepare for the upcoming season. Morata's arrival marks another statement signing for Como, who are keen to strengthen their squad and establish themselves as a competitive force in Serie A. Ahmedabad Plane Crash Ravi kumar jha is an undergraduate student in Bachelor of Arts in Multimedia and Mass Communication. A media enthusiast who has a strong hold on communication and he also has a genuine interest in sports. Ravi is currently working as a journalist at
Business Upturn
9 hours ago
- Business Upturn
Zydus Lifesciences gets USFDA nod for Prucalopride tablets, 1 mg and 2 mg
Zydus Lifesciences Limited has received final approval from the US Food and Drug Administration (USFDA) to market Prucalopride Tablets, 1 mg and 2 mg (reference listed drug: Motegrity® ). The tablets are indicated for the treatment of chronic idiopathic constipation (CIC) — a condition in which the cause of constipation is unknown and persistent. Prucalopride works by stimulating natural peristalsis in the colon, thereby aiding regular bowel movements. With this approval, Zydus adds another feather to its cap in the US generics market. The approved tablets will be manufactured at the company's SEZ facility in Ahmedabad, Gujarat. According to IQVIA MAT data for June 2025, Prucalopride tablets had annual sales of USD 186.8 million in the US market. This approval strengthens Zydus' position in the gastrointestinal segment and adds to its growing US portfolio. With this latest nod, the group has now received 422 approvals since it began filing ANDAs (Abbreviated New Drug Applications) in FY 2003-04. In total, Zydus has filed 483 ANDAs so far. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
9 hours ago
- Business Upturn
Dr. Reddy's Laboratorie gets EIR from USFDA for Telangana facility with VAI status
By Aman Shukla Published on August 8, 2025, 16:24 IST Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its API manufacturing facility (CTO 5) in Miryalaguda, Telangana. The EIR was issued on August 7, 2025, following a GMP inspection that was earlier conducted and disclosed by the company on May 24, 2025. The USFDA has classified the outcome of the inspection as 'Voluntary Action Indicated (VAI)' , meaning the agency has closed the inspection with some observations, but no further regulatory action is anticipated at this time. The inspection is officially considered closed under 21 CFR 20.64(d)(3). A VAI classification typically indicates that the facility remains compliant for continued supply to the US market. This update should bring some regulatory clarity and comfort to stakeholders and investors. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
